CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 102 enrolled
Drug / intervention
tisotumab vedotindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03438396
NCT03438396Phase 2Completed
CompareCT.gov

A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer

Seagen Inc.·interventional·Posted Feb 19, 2018·Updated Jul 25, 2023

In Brief

A Phase 2 clinical trial evaluating tisotumab vedotin for Cervical Cancer. Completed, enrolled 102 participants across 53 sites in 8 countries.

Detailed Summary

A Single arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCervical Cancer
CountriesBelgium, Czechia, Denmark, Germany, Italy, Spain, Sweden, United States
CollaboratorsGenmab, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgian Gynaecological Oncology Group, Gynecologic Oncology Group

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedFeb 19, 2018
Enrollment StartJun 12, 2018
Primary CompletionFeb 6, 2020
Study CompletionAug 2, 2022
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 8.4 years ago

Interventions

tisotumab vedotindrug

All patients will be treated with tisotumab vedotin once every three weeks until progression or toxicity